Tonix Pharmaceuticals Holding Corp. (TNXP) Investor Relations Documents

Tonix Pharmaceuticals Holding Corp. (TNXP) investor relations documents from the company's IR site: 4 presentations, 36 press releases; latest deck 2026-08-10. Read in-app with summaries. First-party data.

2Q'26 Call Presentation: Tonix Pharmaceuticals reported $11 million in Q2 2026 net sales for TONMYA, reflecting 197% QoQ growth, and maintains $176.2 million in cash with no debt.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-10Press releaseTonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
2026-08-10Earnings deck2Q'26 Call Presentation
2026-08-05Press releaseTonix Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-08-03Press releaseTonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-
2026-08-03PresentationTNX-4800 for Lyme Disease Prevention in the U.S.
2026-07-27Press releaseTonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
2026-07-15Press releaseTonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Out
2026-07-13Press releaseTonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®
2026-06-29Press releaseTonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major
2026-06-11Press releaseTonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026
2026-06-08Press releaseTonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52
2026-05-28Press releaseTonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgi
2026-05-17PresentationTNX-1500 for Prevention of Kidney Transplant Rejection and Autoimmune Disorders: 2nd Richard Slayman Clinical Xenotransp
Press releaseHTML
2026-05-11Press releasePDF
PresentationTonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio
2026-03-12Press releaseEarnings Release
Press releaseTonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYA™ at the 8th International Congress on Contro
2026-01-06Press releaseTonix Pharmaceuticals to Present at Two Investor Conferences in January 2026
Press releaseTonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights
Press releaseTonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights
Press releaseTonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights
2025-03-18Press releaseEarnings Release
2025-03-18Press releaseTonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
2025-03-18Press releasePDF: Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
2024-11-12Press releaseEarnings Release
2024-11-12Press releasePDF: Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights
2024-08-19Press releaseEarnings Release
2024-08-19Press releasePDF: Tonix Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Highlights
2024-05-13Press releaseEarnings Release
2024-04-01Press releaseEarnings Release
2023-11-09Press releaseEarnings Release
2023-08-10Press releaseEarnings Release
2023-05-08Press releaseEarnings Release
2023-03-13Press releaseEarnings Release
2022-11-07Press releaseEarnings Release
2022-08-08Press releaseEarnings Release
2022-05-09Press releaseEarnings Release
2022-03-14Press releaseEarnings Release
2021-11-08Press releaseEarnings Release

TNXP overview · TNXP earnings · TNXP financials · TNXP KPIs · TNXP ownership · TNXP peers · TNXP filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.